Anti-Human PDCD1 Recombinant Antibody Fab Fragment (PD1-17) (CAT#: TAB-0961CL-F(E))

Chen, Yundi, et al. "Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy." Bioactive materials 9 (2022): 251-265. https://doi.org/10.1016/j.bioactmat.2021.07.012

This research focuses on engineered extracellular vesicles (EVs) for concurrent immunotherapy and chemotherapy targeting cancer. The study developed EVs that overexpress high-affinity variant PD-1 protein (havPD-1) while simultaneously knocking out PD-L1 and beta-2 microglobulin in donor cells. These engineered havPD-1 EVs demonstrated multiple therapeutic effects: they reduced PD-L1+ cancer cell proliferation, induced cellular apoptosis, efficiently blocked PD-L1 mediated T cell suppression, and showed robust anti-tumor activity in xenograft models. Furthermore, the researchers enhanced therapeutic efficacy by loading the EVs with PARP inhibitors, creating a dual-action delivery system that combines immune checkpoint inhibition with targeted chemotherapy.
Creative Biolabs provided anti-PD-1 antibody Fab fragments (TAB-0961CL-F(E)) for the study. These antibody fragments were crucial for characterizing and quantifying havPD-1 molecules on the EV surface through immunogold labeling techniques. This contribution enabled precise visualization and estimation of havPD-1 protein density on the engineered EVs, which was essential for understanding the relationship between havPD-1 expression levels and the therapeutic efficacy of these novel drug delivery vehicles against cancer cells.